China Oncology ›› 2023, Vol. 33 ›› Issue (4): 327-341.doi: 10.19401/j.cnki.1007-3639.2023.04.003
• Article • Previous Articles Next Articles
XIAO Lanshu1(), PAN Liudi1, LIU Yi1, WANG Jie2, CHEN Hui1()
Received:
2022-12-06
Revised:
2023-03-16
Online:
2023-04-30
Published:
2023-05-15
Contact:
CHEN Hui
CLC Number:
XIAO Lanshu, PAN Liudi, LIU Yi, WANG Jie, CHEN Hui. LncRNA DLEU7-AS1 contributes to proliferation and migration of gastric cancer by regulating MSN transcription[J]. China Oncology, 2023, 33(4): 327-341.
Fig. 1
The expression of DLEU7-AS1 in gastric cancer A: Analysis of DLEU7-AS1 expression in normal and gastric tumor tissues using TCGA database; B: The result of RTFQ-PCR in 37 pairs of gastric cancer tissues and para-cancerous tissues from Xinhua Hospital; C: The relative expression of DLEU7-AS1 in 6 gastric cancer cell lines; D: The distribution of DLEU7-AS1 in cells. ***: P<0.001, compared with control group."
Fig. 3
The correlation between the expression of DLEU7-AS1 and the survival of gastric cancer patients A: The disease-free survival of gastric cancer patients with low and high expression of DLEU7-AS1; B: The post-progression survival of gastric cancer patients with low and high expression of DLEU7-AS1."
Fig. 4
DLEU7-AS1 silence inhibited proliferation of gastric cancer cells A: The expression of DLEU7-AS1 after transfecting siRNA into HGC-27 and AGS; B: Monitoring gastric cancer cells proliferation by CCK-8 after knockdown DLEU7-AS1. *: P<0.05, compared with si-NC; **: P<0.01, compared with si-NC, Student’s t test."
Fig. 5
DLEU7-AS1 promoted proliferation of gastric cancer cells A: The expression of DLEU7-AS1 after transfecting DLEU7-AS1 plasmids into MGC-803 and MKN-45; B: Monitoring gastric cancer cells proliferation by CCK-8 after DLEU7-AS1 overexpression; C: Monitoring gastric cancer cells proliferation by colony formation assay after DLEU7-AS1 overexpression. *: P<0.05, compared with Con260; **: P<0.01, compared with Con260; ***: P<0.001, compared with Con260; ****: P<0.000 1, compared with Con260; Student’s t test."
Fig. 10
DLEU7-AS1 regulated MSN expression A: Volcano plot of differential genes by RNA-seq analysis of HGC-27 transfected with si-491 and si-NC; B: RTFQ-PCR analysis of MSN mRNA level after transfection of si-RNA and si-491 in AGS and HGC-27; C: RTFQ-PCR analysis of MSN mRNA level after DLEU7-AS1 overexpression in MGC-803 and SGC-7901; D: Western blot analysis of MSN protein expression level after transfection of si-RNA and si-491 in AGS and HGC-27. *: P<0.05, compared with si-NC/Con260; **: P<0.01, compared with si-NC/Con260; ***: P<0.001, compared with si-NC/Con260."
Fig. 11
MSN acted as downstream effector of DLEU7-AS1 A: Transwell chamber assay after knockdown of DLEU7-AS1 and overexpression of MSN; B: CCK-8 cell proliferation toxicity test after knockdown of DLEU7-AS1 and overexpression of MSN. ***: P<0.001, si-NC + CON468 compared with si-491 + CON468; *: P<0.05, si-NC + CON468 compared with si-NC + MSN; **: P<0.01, si-491 + CON468 compared with si-491 + MSN; **: P<0.01, si-491 + CON468 compared with si-491 + MSN; *: P<0.05, si-NC + CON468 compared with si-491+CON468, Student’s t test."
Fig. 12
The expression of MSN in gastric cancer and the correlation between the expression of MSN and the survival of gastric cancer patients A and B: Analysis of MSN expression in normal and gastric tumor tissues using GEPIA2 database; C: The disease-free progressive survival of gastric cancer patients with low and high expression of MSN; D: The post-progression survival of gastric cancer patients with low and high expression of MSN. *: P<0.05, compared with control."
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3 |
[2] |
SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. The Lancet, 2020, 396(10251): 635-648.
doi: 10.1016/S0140-6736(20)31288-5 |
[3] |
QIU H B, CAO S M, XU R H. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun, 2021, 41(10): 1037-1048.
doi: 10.1002/cac2.v41.10 |
[4] |
CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2): 115-132.
doi: 10.3322/caac.21338 |
[5] | XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. |
[6] |
HERMAN A B, TSITSIPATIS D, GOROSPE M. Integrated lncRNA function upon genomic and epigenomic regulation[J]. Mol Cell, 2022, 82(12): 2252-2266.
doi: 10.1016/j.molcel.2022.05.027 pmid: 35714586 |
[7] |
HUARTE M. The emerging role of lncRNAs in cancer[J]. Nat Med, 2015, 21(11): 1253-1261.
doi: 10.1038/nm.3981 pmid: 26540387 |
[8] | TAN Y T, LIN J F, LI T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer[J]. Cancer Commun (Lond), 2021, 41(2): 109-120. |
[9] |
JUSIC A, THOMAS P B, WETTINGER S B, et al. Noncoding RNAs in age-related cardiovascular diseases[J]. Ageing Res Rev, 2022, 77: 101610.
doi: 10.1016/j.arr.2022.101610 |
[10] |
SUN P, HAMBLIN M H, YIN K J. Non-coding RNAs in the regulation of blood-brain barrier functions in central nervous system disorders[J]. Fluids Barriers CNS, 2022, 19(1): 27.
doi: 10.1186/s12987-022-00317-z pmid: 35346266 |
[11] | LIU X B, HAN C, SUN C Z. Long non-coding RNA DLEU7-AS1 promotes the occurrence and development of colorectal cancer via Wnt/β-catenin pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1): 110-117. |
[12] |
WANG X J, CHEN L, XU R, et al. DLEU7-AS1 promotes renal cell cancer by silencing the miR-26a-5p/coronin-3 axis[J]. Clin Kidney J, 2022, 15(8): 1542-1552.
doi: 10.1093/ckj/sfac061 |
[13] | WANG C Z, MA B B, XU Z J, et al. Reduced expression of lncRNA DLEU7-AS1 is a novel favorable prognostic factor in acute myeloid leukemia[J]. Biosci Rep, 2022, 42(5): BSR20212078. |
[14] |
ENCODE PROJECT CONSORTIUM. An integrated encyclopedia of DNA elements in the human genome[J]. Nature, 2012, 489(7414): 57-74.
doi: 10.1038/nature11247 |
[15] |
HUANG W X, LI H, YU Q S, et al. LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond[J]. J Exp Clin Cancer Res, 2022, 41(1): 100.
doi: 10.1186/s13046-022-02319-z |
[16] |
LI K, WANG Z Q. lncRNA NEAT1: key player in neurodegenerative diseases[J]. Ageing Res Rev, 2023, 86: 101878.
doi: 10.1016/j.arr.2023.101878 |
[17] | NOJIMA T, PROUDFOOT N J. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics[J]. Nat Rev Mol Cell Biol, 2022, 23(6): 389-406. |
[18] |
LIU J, LIU Z X, WU Q N, et al. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming[J]. Nat Commun, 2020, 11(1): 1507.
doi: 10.1038/s41467-020-15112-3 pmid: 32198345 |
[19] |
JI X S, LIU Z H, GAO J J, et al. N6-Methyladenosine-modified lncRNA LINREP promotes glioblastoma progression by recruiting the PTBP1/HuR complex[J]. Cell Death Differ, 2023, 30(1): 54-68.
doi: 10.1038/s41418-022-01045-5 |
[20] |
MCCABE E M, RASMUSSEN T P. lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions[J]. Semin Cancer Biol, 2021, 75: 38-48.
doi: 10.1016/j.semcancer.2020.12.012 pmid: 33346133 |
[21] |
LIU H, LI D X, SUN L N, et al. Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression[J]. Mol Cancer, 2022, 21(1): 74.
doi: 10.1186/s12943-022-01555-3 |
[22] |
LI Z, LANG Z Q, WANG T, et al. LncRNA SNHG22 promotes gastric cancer progression by regulating the miR-101-3p/e2f2 axis[J]. Cell Cycle, 2023, 22(3): 347-360.
doi: 10.1080/15384101.2022.2119515 |
[23] |
LIN Z H, SONG J L, GAO Y K, et al. Hypoxia-induced HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer[J]. Redox Biol, 2022, 52: 102312.
doi: 10.1016/j.redox.2022.102312 |
[24] |
MANGEAT P, ROY C, MARTIN M. ERM proteins in cell adhesion and membrane dynamics[J]. Trends Cell Biol, 1999, 9(5): 187-192.
pmid: 10322453 |
[25] |
DEGRYSE B, BRITTO M, SHAN C X, et al. Moesin and merlin regulate urokinase receptor-dependent endothelial cell migration, adhesion and angiogenesis[J]. Int J Biochem Cell Biol, 2017, 88: 14-22.
doi: S1357-2725(17)30090-0 pmid: 28473293 |
[26] |
LI Y Q, ZHENG Z, LIU Q X, et al. Moesin as a prognostic indicator of lung adenocarcinoma improves prognosis by enhancing immune lymphocyte infiltration[J]. World J Surg Oncol, 2021, 19(1): 109.
doi: 10.1186/s12957-021-02229-y |
[27] |
SUN X, LI K X, HASE M, et al. Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling[J]. Theranostics, 2022, 12(2): 929-943.
doi: 10.7150/thno.66148 pmid: 34976221 |
[28] |
YU L F, ZHAO L, WU H Z, et al. Moesin is an independent prognostic marker for ER-positive breast cancer[J]. Oncol Lett, 2019, 17(2): 1921-1933.
doi: 10.3892/ol.2018.9799 pmid: 30675256 |
[29] |
KAMIOKA H, TOMONO T, FUJITA A, et al. Moesin-mediated P-glycoprotein activation during snail-induced epithelial-mesenchymal transition in lung cancer cells[J]. J Pharm Sci, 2020, 109(7): 2302-2308.
doi: 10.1016/j.xphs.2020.03.008 |
[1] | JIANG Jinling, ZHOU Chenfei, WANG Chao, ZHAO Liqin, WU Junwei, ZHANG Jun. Advanced progress in research and diagnosis of gastric cancer in 2022 [J]. China Oncology, 2023, 33(4): 303-314. |
[2] | CHEN Hong, CHEN Junxia. Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(4): 342-353. |
[3] | PENG Jin, WANG Weining, TAN Zhi, YE Guannan, ZHOU Zhen. The mechanism of m6Am-modifying enzyme PCIF1 regulating target gene ACOT8 in gastric cancer progression [J]. China Oncology, 2023, 33(4): 368-376. |
[4] | LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun. The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy [J]. China Oncology, 2023, 33(4): 377-387. |
[5] | FU Qingsheng, JIN Lei, ZHANG Xudong, XU Yingchen, ZHU Chunfu, QIN Xihu, WU Baoqiang. Effect of tRF-Pro-CGG on the biological behavior of mouse pancreatic cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(3): 241-249. |
[6] | CHEN Xinning, JIANG Huiqin, YANG Yihui, YU Qian, ZHANG Chunyan, WANG Beili, PAN Baishen, GUO Wei. Expression of plasma methylated Septin9 gene and its clinical significance in patients with gastric cancer [J]. China Oncology, 2023, 33(2): 162-167. |
[7] | WANG Xiaoxiao, CHEN Xi, LI Minmin, SONG Ning, SUN Dongyuan, JIANG Yingying. Effects of NOL8 on cell proliferation, migration and invasion of oral squamous cell carcinoma [J]. China Oncology, 2023, 33(1): 45-53. |
[8] | ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells [J]. China Oncology, 2022, 32(9): 818-826. |
[9] | CAI Gang, WANG Shubei, CHEN Jiayi. The current data and challenge of radiotherapy in the case management of gastric cancer [J]. China Oncology, 2022, 32(7): 581-587. |
[10] | CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong. Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer [J]. China Oncology, 2022, 32(7): 588-595. |
[11] | JIANG Jinling, ZHOU Chenfei, XI Wenqi, SHI Min, GEN Mei, ZHAO Liqin, CAI Qu, JIANG Jinsong, ZHANG Jun. Optimization of 5-FU metronomic chemotherapy strategy and regulation of the immune microenvironment in gastric cancer: an in vivo study [J]. China Oncology, 2022, 32(7): 596-605. |
[12] | DUAN Yuqing, XIA Ning, JIA Yunlong, ZHENG Wenya, LIU Lihua. SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing [J]. China Oncology, 2022, 32(3): 191-199. |
[13] | ZHU Haipeng, HU Jun, JIANG Min, CAI Ruonan, WANG Junqiao, LI Li. A study on mechanism of GOLM1 regulating PI3K/AKT/mTOR signaling pathway to promote proliferation, invasion and migration of lung adenocarcinoma cells [J]. China Oncology, 2022, 32(3): 207-217. |
[14] | CHEN Xi, ZENG Xiaoying, CHEN Jiayan, LIU Fei, TANG Xi. The clinical value of mismatch repair protein combined with serum tumor markers and Ki-67 proliferation index in the prognostic evaluation of colorectal cancer [J]. China Oncology, 2022, 32(3): 243-250. |
[15] | ZHU Yi, XIAO Bin, LIU Jiahui, HUANG Ling, SUN Zhaohui, LI Linhai. Expression, localization, biological role and proteomics study of circ-0003910 in HER2-positive breast cancer [J]. China Oncology, 2022, 32(10): 979-989. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd